Abstract:Background The interplay between the gut microbiome and immune responses in cancer remains poorly understood. We showed that gut microbiome changes are closely associated with development of lung adenocarcinoma (LUAD) in a human-relevant, tobacco-associated mouse model (Gprc5a-/-; G).1 Knockout of the antimicrobial protein Lcn2 (Gprc5a-/-/Lcn2-/-; GL) further reduced microbial diversity while enhancing inflammation and tumor development.1 We thus hypothesized that microbial dysbiosis in the gut, such as that incurred by loss of Lcn2, may exacerbate LUAD development and influence response to immune checkpoint blockade (ICB). Methods We used fecal microbiota transfer (FMT) in syngeneic and tobacco carcinogenesis models. Gut microbiome composition was assessed using 16S rDNA-Seq analysis, chemokines were quantified in murine sera, and the tumor immune microenvironment (TIME) and gut immune milieu were comprehensively studied using single-cell RNA-sequencing and flow cytometry. Results Syngeneic G mice receiving FMT from GL donors (G < GL) exhibited significantly increased tumor growth compared to G < G mice. This effect was recapitulated in an independent syngeneic model (KrasG12D LKR13 cells in wild-type mice) and tobacco carcinogen-exposed G < GL mice. Analysis of fecal pellets using 16S rDNA-Seq revealed significant differences in gut beta diversity between G < G and G < GL mice, with elevated abundance of tumor-promoting Alistipes2 and reduced levels of immunotherapy-favorable taxa Ruminoccocus and Akkermansia.3 Flow cytometry analysis of the colonic lamina propria demonstrated an inflamed environment in G < GL mice with increased inflammatory immune cell frequency. This local gut inflammation was accompanied by a systemic inflammatory response, as indicated by elevated inflammatory chemokines in the sera. Single-cell RNA-sequencing and flow cytometry analysis of tumors revealed an enhanced immunosuppressive phenotype in the TIME of G < GL mice, including increased fractions of T regulatory and exhausted T cells, along with reduced levels of activated T cells. Flow cytometry confirmed enhanced immunosuppression in G < GL mice, including increased fractions of myeloid-derived suppressor cells in the TIME. The dysbiotic gut, with its associated systemic inflammation and immunosuppression of the TIME, significantly impacted the response to ICB, with G < GL mice demonstrating reduced response and sensitivity to anti-PD1 treatment compared to G < G mice. Conclusions Our findings show that gut microbiome dysbiosis fosters lung cancer development by promoting immunosuppression, perhaps via a local and systemic gut microbiota-immune system crosstalk (figure 1). Modulating the gut microbiome may offer promising strategy for interception or early treatment of lung cancer. Acknowledgements Supported in part by National Cancer Institute (NCI) grants R01CA205608 and R01CA248731 (to H. Kadara). References Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, et al. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci. 2022;23(18):10930. Available online: https://doi.org/10.3390/ijms231810930 Moschen AR, Gerner RR, Wang J, Klepsch V, Adolph TE, Reider SJ, Hackl H, Pfister A, Schilling J, Moser PL, Kempster SL, Swidsinski A, Orth Höller D, Weiss G, Baines JF, Kaser A, Tilg H. Lipocalin 2 Protects from Inflammation and Tumorigenesis Associated with Gut Microbiota Alterations. Cell Host Microbe. 2016;19(4):455–469. doi: 10.1016/j.chom.2016.03.007 Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–514. doi: 10.1038/s41591–020-01224–2

Lung Microbiome Intervention Attenuates Herpesvirus-Induced Post-HCT Pulmonary Fibrosis Through PD-L1 Upregulation on Dendritic Cells

The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Safety and Efficacy of Anti-Pd-1 Inhibitors in Chinese Patients with Advanced Lung Cancer and Hepatitis B Virus Infection: a Retrospective Single-Center Study

The Critical Role of Induced CD4+ FoxP3+ Regulatory Cells in Suppression of Interleukin-17 Production and Attenuation of Mouse Orthotopic Lung Allograft Rejection.

A Novel MyD88 Inhibitor Attenuates Allograft Rejection after Heterotopic Tracheal Transplantation in Mice

Abstract 620: Associations of Genomic Alteration, Tumor Mutational Burden with PD-L1 Expression and Response to Immune Checkpoint Inhibitors in Chinese Lung Patients

The Potential Role of Lung Microbiota and Lauroylcarnitine in T-cell Activation Associated with Checkpoint Inhibitor Pneumonitis

Abstract 4116: Modulating gut microbiota to improve intrahepatic immunity against hepatocellular cancer

Phenotypes, Lung Microbiota and Cytokine Responses in Pneumonia after Hematopoietic Stem Cell Transplantation.

Horizontal transmission of gut microbiota attenuates mortality in lung fibrosis

Impact of Pulmonary microbiota on lung cancer treatment-related pneumonia

Correlation of HERVK with Efficacy on Anti-Pd-1/pd-l1 Therapy in a Pilot Metagenomics Study on Chinese Advanced Lung Cancer Patients.

Alterations in circulating measures of Th2 immune responses pre-lung transplant associates with reduced primary graft dysfunction

Targeting PD-1/PD-L1 inhibits rejection in a heterotopic tracheal allograft model of lung transplantation

1330 Gut Microbiome Dysbiosis Promotes Immune Suppression and Lung Cancer Development

Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation

Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation

Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model

Abstract 1825: A bacterial consortium engineered from feces of patients responding to anti-PD1 treatment mediates tumor response through IFNγ in non-small cell lung cancer

Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice